Quality of Life in Cystic Fibrosis

PharmacoEconomics

Volumn 8, Issue 1, 1995, Pages 23-33

  Tullis, D Elizabeth ^a,b   Guyatt, Gordon H ^c  

^a WELLESLEY HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Department of Medicine ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ANTIBIOTIC AGENT; DORNASE ALFA; ENZYME; MUCOLYTIC AGENT;

CYSTIC FIBROSIS; DISEASE SEVERITY; GENE THERAPY; GENETIC DISORDER; HEALTH; HEALTH INSURANCE; HUMAN; LUNG FUNCTION; MEASUREMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

CYSTIC FIBROSIS; HUMAN; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE;

EID: 0029069491     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-199508010-00005     Document Type: Review

References (49)

1. Cystic fibrosis of the pancreas and its relation to coeliac disease
2. Cystic fibrosis: part I
3. The changing epidemiology of cyslic fibrosis
4. Identificalion of the cystic fibrosis gene: chromosome walking and jumping
5. Identification of the cystic fibrosis gene: cloning and characterisation of complementary DNA
6. Identiftcation of the cystic fibrosis gene: genetic analysis
7. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator
8. In vivo cell-specific expression of the cystic fibrosis transmembrane conductance regulator
9. Gastrointestinal manifestations of cystic fibrosis: a review
10. Reproductive defects in patients of both sexes with cystic fibrosis: a review
11. Water and electrolyteS in cervical mucus from patients with cystic fibrosis
12. The relation between genotype and phenotype in cystic fibrosis–analysis of the most common mutation (F508)
13. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis
14. Efficacy and safety of short term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis
15. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
16. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis
17. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to airway epithelium
18. Prediction of mortality in patients with cystic fibrosis
19. The chest roentgenogram in cystic fibrosis: a new scoring system
20. Long-term study of one hundred five patients with cystic fibrosis
21. A new prognostic score and clinical evaluation system for cystic fibrosis
22. Negative clinical trials in cystic fibrosis research
23. Clinical-behavioral aspects of cystic fibrosis: directions for future research
24. Preamble to the constitution of the World Health Organization
25. Growing older with cystic fibrosis: psychologic adjustment of patients more than 16 years old
26. The development of psychiatric symptomatology in patients with cystic fibrosis
27. Psychological effects of illness in adolescence: I. Anxiety, self eSteem and perception of control
28. Chronic disease and its impact the adolescent’s perspective
29. A comparative study of the psychosocial assets of adults with cystic fibrosis and their healthy peers
30. Functional status as an overall measure of health in adults with cystic fibrosis: further validation of a generic health measure
31. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study
32. Comparison of Quali!y of Well-Being Scale and Functional Status Index in patients with atrial fibrillation
33. Health-related quality of life measurement for evaluation, research and policy analysis
34. A general health policy model: update and applications
35. The reliabili!y, stability and genca]iubi]i!y of a health Status index
36. The quality of well-being in cystic fibrosis
37. Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease
38. Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis
39. Measuring the quality of well-being in cystic fibrosis and lung transplantation
40. The quality of well-being scale: application in AIDS, cystic fibrosis, and arthritis
41. The Nottingham Health Profile
42. Measuring health status: a new tool for clinicians and epidemiologists
43. Survival and quality of life of cystic fibrosis patients before and after heart lung transplantation
44. Measuring diseasespecifiC quality of life in clinical trials
45. The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection
46. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs
47. Validating the SF-36 health survey questionnaire: new outcome measure for primary care
48. Measurement of health state utilities for economic appraisal